» Articles » PMID: 26104935

Hypercellularity Components of Glioblastoma Identified by High B-Value Diffusion-Weighted Imaging

Overview
Specialties Oncology
Radiology
Date 2015 Jun 25
PMID 26104935
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Use of conventional magnetic resonance imaging (MRI) for target definition may expose glioblastomas (GB) to inadequate radiation dose coverage of the nonenhanced hypercellular subvolume. This study aimed to develop a technique to identify the hypercellular components of GB by using high b-value diffusion-weighted imaging (DWI) and to investigate its relationship with the prescribed 95% isodose volume (PDV) and progression-free survival (PFS).

Methods And Materials: Twenty-one patients with GB underwent chemoradiation therapy post-resection and biopsy. Radiation therapy (RT) treatment planning was based upon conventional MRI. Pre-RT DWIs were acquired in 3 orthogonal directions with b-values of 0, 1000, and 3000 s/mm(2). Hypercellularity volume (HCV) was defined on the high b-value (3000 s/mm(2)) DWI by a threshold method. Nonenhanced signified regions not covered by the Gd-enhanced gross tumor volume (GTV-Gd) on T1-weighted images. The PDV was used to evaluate spatial coverage of the HCV by the dose plan. Association between HCV and PFS or other clinical covariates were assessed using univariate proportional hazards regression models.

Results: HCVs and nonenhanced HCVs varied from 0.58 to 67 cm(3) (median: 9.8 cm(3)) and 0.15 to 60 cm(3) (median: 2.5 cm(3)), respectively. Fourteen patients had incomplete dose coverage of the HCV, 6 of whom had >1 cm(3) HCV missed by the 95% PDV (range: 1.01-25.4 cm(3)). Of the 15 patients who progressed, 5 progressed earlier, within 6 months post-RT, and 10 patients afterward. Pre-RT HCVs within recurrent GTVs-Gd were 78% (range: 65%-89%) for the 5 earliest progressions but lower, 53% (range: 0%-85%), for the later progressions. HCV and nonenhanced HCV were significant negative prognostic indicators for PFS (P<.002 and P<.01, respectively). The hypercellularity subvolume not covered by the 95% PDV was a significant negative predictor for PFS (P<.05).

Conclusions: High b-value DWI identifies the hypercellular components of GB and could aid in RT target volume definition. Future studies will allow us to investigate the role of high b-value DWI in identifying radiation boost volumes and diagnosing progression.

Citing Articles

Imaging features and consideration of progression pattern of diffuse hemispheric gliomas, H3 G34-mutant.

Kibe Y, Chalise L, Ohka F, Motomura K, Nakahara N, Aoki K Acta Neuropathol Commun. 2025; 13(1):43.

PMID: 40016857 PMC: 11866785. DOI: 10.1186/s40478-025-01945-w.


Direct real-time intra-operative imaging of human brain tumour vessels using intravital microscopy.

Garcia D, Gabriel E, Quinones-Hinojosa A Clin Transl Med. 2024; 14(12):e70084.

PMID: 39639539 PMC: 11621231. DOI: 10.1002/ctm2.70084.


Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy.

Peng H, Deng J, Jiang S, Timmerman R Front Oncol. 2024; 14:1357790.

PMID: 38571510 PMC: 10987838. DOI: 10.3389/fonc.2024.1357790.


Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.

Tseng C, Zeng K, Mellon E, Soltys S, Ruschin M, Lau A Neuro Oncol. 2024; 26(12 Suppl 2):S3-S16.

PMID: 38437669 PMC: 10911794. DOI: 10.1093/neuonc/noad258.


Integrating multi-modal imaging in radiation treatments for glioblastoma.

Breen W, Aryal M, Cao Y, Kim M Neuro Oncol. 2024; 26(12 Suppl 2):S17-S25.

PMID: 38437666 PMC: 10911793. DOI: 10.1093/neuonc/noad187.


References
1.
Jensen J, Helpern J, Ramani A, Lu H, Kaczynski K . Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med. 2005; 53(6):1432-40. DOI: 10.1002/mrm.20508. View

2.
Salphati L, Heffron T, Alicke B, Nishimura M, Barck K, Carano R . Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res. 2012; 18(22):6239-48. DOI: 10.1158/1078-0432.CCR-12-0720. View

3.
Grosu A, Weber W, Franz M, Stark S, Piert M, Thamm R . Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(2):511-9. DOI: 10.1016/j.ijrobp.2005.01.056. View

4.
Pope W, Sayre J, Perlina A, Villablanca J, Mischel P, Cloughesy T . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005; 26(10):2466-74. PMC: 7976216. View

5.
Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View